Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM120 in Colorectal Cancer with Cancer Cachexia
NCT07033026Phase 2Recruiting
- Sponsor
- NGM Biopharmaceuticals
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of NGM120 in cancer cachexia, sponsored by NGM Biopharmaceuticals. Started Jun 2025; status: recruiting.
02
Drugs
NGM120
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT07033026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033026.